|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0006142,
umls-concept:C0038952,
umls-concept:C0039286,
umls-concept:C0041700,
umls-concept:C0205369,
umls-concept:C0205419,
umls-concept:C0332293,
umls-concept:C0599755,
umls-concept:C1332830,
umls-concept:C1516213,
umls-concept:C1522673
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-10-5
|
|
pubmed:abstractText |
Tamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene. CYP2D6 variants resulting in poor metabolism of tamoxifen are hypothesised to reduce its efficacy. An FDA-approved pre-treatment CYP2D6 gene testing assay is available. However, evidence from published studies evaluating CYP2D6 variants as predictive factors of tamoxifen efficacy and clinical outcome are conflicting, querying the clinical utility of CYP2D6 testing. We investigated the association of CYP2D6 variants with breast cancer specific survival (BCSS) in breast cancer patients receiving tamoxifen.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1465-542X
|
|
pubmed:author |
pubmed-author:AbrahamJean EJE,
pubmed-author:BaynesCarolineC,
pubmed-author:CaldasCarlosC,
pubmed-author:DriverKristy EKE,
pubmed-author:DunningAlison MAM,
pubmed-author:EarlHelena MHM,
pubmed-author:GreenbergDavidD,
pubmed-author:IngleSusanS,
pubmed-author:KalmyrzaevBolotB,
pubmed-author:LuccariniCraigC,
pubmed-author:MaranianMel JMJ,
pubmed-author:PharoahPaul D PPD,
pubmed-author:PlatteRadkaR,
pubmed-author:ShahMitulM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
R64
|
|
pubmed:dateRevised |
2011-10-28
|
|
pubmed:meshHeading |
pubmed-meshheading:20731819-Adult,
pubmed-meshheading:20731819-Aged,
pubmed-meshheading:20731819-Antineoplastic Agents, Hormonal,
pubmed-meshheading:20731819-Breast Neoplasms,
pubmed-meshheading:20731819-Chemotherapy, Adjuvant,
pubmed-meshheading:20731819-Cohort Studies,
pubmed-meshheading:20731819-Cytochrome P-450 CYP2D6,
pubmed-meshheading:20731819-Female,
pubmed-meshheading:20731819-Gene Frequency,
pubmed-meshheading:20731819-Genotype,
pubmed-meshheading:20731819-Great Britain,
pubmed-meshheading:20731819-Humans,
pubmed-meshheading:20731819-Middle Aged,
pubmed-meshheading:20731819-Polymorphism, Single Nucleotide,
pubmed-meshheading:20731819-Proportional Hazards Models,
pubmed-meshheading:20731819-Survival Analysis,
pubmed-meshheading:20731819-Tamoxifen,
pubmed-meshheading:20731819-Treatment Outcome,
pubmed-meshheading:20731819-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
|
|
pubmed:affiliation |
Department of Oncology, Strangeways Research Laboratory, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK. ja344@medschl.cam.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
